|
|
|
|
|
|
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
A Phase I Study of OTS167PO, a MELK inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients with Advanced Breast Cancer and Dose-Expansion Study in Patients with Triple Negative Breast Cancer. - OTS1070103
/ Active, not recruiting临床1期 A Phase I Study of OTS167PO, a MELK Inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients with Advanced Breast Cancer and Dose-Expansion Study in Patients with Triple Negative Breast Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.
A phase 1, randomised, placebo-controlled, double-blind, cross-over study to evaluate systemic bioavailability of oral OTS167 under fed and fasting conditions in healthy adult subjects.
100 项与 NLK x hMELK 相关的临床结果
100 项与 NLK x hMELK 相关的转化医学
0 项与 NLK x hMELK 相关的专利(医药)